ClinicalTrials.gg
CompletedNCT07083817Updated Aug 29, 2025

Mass Balance Study of [14C]Xeruborbactam (QPX7728) in Healthy Adult Male Participants

A Phase 1 interventional study of [14C]Xeruborbactam in ADME, sponsored by Qpex Biopharma, Inc.. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-29.

Sponsored by Qpex Biopharma, Inc. (part of Shionogi) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Male
01

Study summary

This is a single-dose, phase 1 open-label study to determine the mass balance recovery and metabolic profiling and identification for intravenous (IV) administered [14C]xeruborbactam. This study will investigate the primary route of excretion, profile [14C]xeruborbactam metabolites in plasma, urine and faeces, and assess the safety, tolerability, and pharmacokinetics (PK) of a single IV dose of [14C]xeruborbactam in healthy adult male participants.

02

Conditions studied

  • ADME
03

In context

Lead sponsor

Qpex Biopharma, Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

First submitted after Qpex Biopharma, Inc. became part of Shionogi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, safety laboratory tests, vital signs, and cardiac (12-lead (ECG)) monitoring.
  • Body weight within 55.0 and 100.0 kg (inclusive) and (BMI) within the range of 18.0 and 32.0 kg/m2 (inclusive).
  • Participants who have regular bowel movements (ie, average stool production of ≥ 1 and ≤ 3 stools per day)
  • use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of giving signed

Exclusion criteria

Exclusion Criteria:

  • History or presence of significant cardiovascular, respiratory/pulmonary, hepatic, renal, hematological, gastrointestinal (GI), endocrine, immunologic, dermatologic, neurological, or psychiatric disease capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the intervention; or interfering with the interpretation of data
  • Surgery within the past 3 months prior to Day 1 determined by the investigator to be
  • History of GI surgery including but not limited to, gastric resection and/or intestinal resection that may result in a clinically significant abnormality in GI function (expect for an appendectomy for noncomplicated appendicitis unless it was performed in the previous 12 months)
  • Acute diarrhea, loose stools, or constipation within 14 days prior to the screening visit or upon admission to the clinical research unit (CRU) (Day -1). Diarrhea will be defined as the passage of liquid faeces and/or a stool frequency of ≥ 3 times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day
  • Lymphoma, leukemia, or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    [14C]Xeruborbactam

    Drug: [14C]Xeruborbactam

Interventions

06

What researchers measure

Primary outcomes

  1. Amount of total radioactivity excreted expressed as a percentage of the radioactive dose administered (Fe)

    Time frame: Day 1 to Day 15

  2. Cumulative amount of total radioactivity excreted expressed as percentage of the radioactive dose administered (CumFe)

    Time frame: Day 1 to Day 15

  3. Ratio of plasma xeruborbactam concentrations relative to total radioactivity based on Cmax

    Time frame: Day 1 to Day 15

  4. Ratio of plasma xeruborbactam concentrations relative to total radioactivity based on AUC0-last

    Time frame: Day 1 to Day 15

  5. Ratio of plasma xeruborbactam concentrations relative to total radioactivity based on AUC0-inf

    Time frame: Day 1 to Day 15

  6. Whole blood to plasma total radioactivity ratio based on Cmax

    Time frame: Day 1 to Day 15

  7. Whole blood to plasma total radioactivity ratio based on AUC0-last

    Time frame: Day 1 to Day 15

  8. Whole blood to plasma total radioactivity ratio based on AUC0-inf

    Time frame: Day 1 to Day 15

  9. Maximum plasma concentration (Cmax) for xeruborbactam

    Time frame: Day 1 to Day 15

  10. Time to maximum plasma concentration (Tmax) for xeruborbactam

    Time frame: Day 1 to Day 15

  11. Area under the concentration time curve from zero to infinity (AUC0-inf) for xeruborbactam

    Time frame: Day 1 to Day 15

  12. Maximum plasma and whole blood concentration (Cmax) of total radioactivity

    Time frame: Day 1 to Day 15

  13. Time to maximum plasma and whole blood concentration (Tmax) of total radioactivity

    Time frame: Day 1 to Day 15

  14. Area under the concentration time curve from zero to infinity (AUC0-inf) of total radioactivity in plasma and whole blood

    Time frame: Day 1 to Day 15

  15. Amount of total radioactivity excreted in urine (Aeu)

    Time frame: Day 1 to Day 15

  16. Amount of total radioactivity excreted in in urine expressed as a percentage of the radioactive dose administered (Feu)

    Time frame: Day 1 to Day 15

  17. Identification of the chemical structure of each metabolite accounting for 5% or more in plasma by area under the time concentration curve (AUC)

    Time frame: Day 1 to Day 15

  18. Identification of the chemical structure of each metabolite in urine and faeces that account for 5% or more of the administered radioactive dose

    Time frame: Day 1 to Day 15

  19. Total amount of radioactivity excreted (Ae)

    Time frame: Day 1 to Day 15

  20. Cumulative amount of total radioactivity excreted (CumAe)

    Time frame: Day 1 to Day 15

  21. Ratio of whole blood to plasma total radioactivity

    Time frame: Day 1 to Day 15

Secondary outcomes

  1. Percentage of participants with Treatment-Emergent Adverse Events

    Time frame: Day 1 to Day 15

07

Study locations

1 site
  • Quotient Sciences
    Nottingham, NG11 6JS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Aug 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Jul 24, 2025
StartActual
Aug 13, 2025
Primary completionActual
Aug 27, 2025
CompletionActual
Aug 27, 2025
Last update
Aug 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07083817
Collaborators
Shionogi Inc.
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
Aug 13, 2025
Primary completion
Aug 27, 2025
Completion
Aug 27, 2025
Last update
Aug 29, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Xeruborbactam

Start the discussion